Journal of Gastric Cancer

  • 제20권3호
  • /
  • Pages.313-327
  • /
  • 2020
  • /
  • 2093-582X(pISSN)
  • /
  • 2093-5641(eISSN)
대한위암학회 (The Korean Gastric Cancer Association)
권호 표지
DOI QR코드

DOI QR Code

Preoperative Therapy Regimen Influences the Incidence and Implication of Nodal Downstaging in Patients with Gastric Cancer

  • Stark, Alexander P. (Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Blum, Mariela M. (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Chiang, Yi-Ju (Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Das, Prajnan (Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Minsky, Bruce D. (Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Estrella, Jeannelyn S. (Department of Pathology, The University of Texas MD Anderson Cancer Center) ;
  • Ajani, Jaffer A. (Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Badgwell, Brian D. (Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Mansfield, Paul (Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center) ;
  • Ikoma, Naruhiko (Department of Surgical Oncology, The University of Texas MD Anderson Cancer Center)
  • 투고 : 2020.04.30
  • 심사 : 2020.09.01
  • 발행 : 2020.09.30
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Purpose: Nodal downstaging after preoperative therapy for gastric cancer has been shown to impart excellent prognosis, but this has not been validated in a national cohort. The role of neoadjuvant chemoradiation (NACR) in nodal downstaging remains unclear when compared with that of neoadjuvant chemotherapy alone (NAC). Furthermore, it is unknown whether the prognostic implications of nodal downstaging differ by preoperative regimen. Materials and Methods: Using the National Cancer Database, overall survival (OS) duration was compared among natural N0 (cN0/ypN0), downstaged N0 (cN+/ypN0), and nodepositive (ypN+) gastric cancer patients treated with NACR or NAC. Factors associated with nodal downstaging were examined in a propensity score-matched cohort of cN+ patients, matched 1:1 by receipt of NACR or NAC. Results: Of 7,426 patients (natural N0 [n=1,858, 25.4%], downstaged N0 [n=1,813, 24.4%], node-positive [n=3,755, 50.4%]), 58.2% received NACR, and 41.9% received NAC. The median OS durations of downstaged N0 (5.1 years) and natural N0 (5.6 years) patients were similar to one another and longer than that of node-positive patients (2.1 years) (P<0.001). In the matched cohort of cN+ patients, more recent diagnosis (2010-2015 vs. 2004-2009) (odds ratio [OR], 2.57; P<0.001) and NACR (OR, 2.02; P<0.001) were independently associated with nodal downstaging. The 5-year OS rate of downstaged N0 patients was significantly lower after NACR (46.4%) than after NAC (57.7%) (P=0.003). Conclusions: Downstaged N0 patients have the same prognosis as natural N0 patients. Nodal downstaging occurred more frequently after NACR; however, the survival benefit of nodal downstaging after NACR may be less than that when such is achieved by NAC.

키워드

참고문헌

  1. National Comprehensive Cancer Network. Gastric cancer (Version 2.2019) [Internet]. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2019 [cited 2020 May 6]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/gastric.pdf.
  2. Greenleaf EK, Hollenbeak CS, Wong J. Trends in the use and impact of neoadjuvant chemotherapy on perioperative outcomes for resected gastric cancer: evidence from the American College of Surgeons National Cancer Database. Surgery 2016;159:1099-1112. https://doi.org/10.1016/j.surg.2015.11.004
  3. Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJ, Nicolson M, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 2006;355:11-20. https://doi.org/10.1056/NEJMoa055531
  4. Schuhmacher C, Gretschel S, Lordick F, Reichardt P, Hohenberger W, Eisenberger CF, et al. Neoadjuvant chemotherapy compared with surgery alone for locally advanced cancer of the stomach and cardia: European Organisation for Research and Treatment of Cancer randomized trial 40954. J Clin Oncol 2010;28:5210-5218. https://doi.org/10.1200/JCO.2009.26.6114
  5. Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: an FNCLCC and FFCD multicenter phase III trial. J Clin Oncol 2011;29:1715-1721. https://doi.org/10.1200/JCO.2010.33.0597
  6. Macdonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001;345:725-730. https://doi.org/10.1056/NEJMoa010187
  7. Smalley SR, Benedetti JK, Haller DG, Hundahl SA, Estes NC, Ajani JA, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J Clin Oncol 2012;30:2327-2333. https://doi.org/10.1200/JCO.2011.36.7136
  8. Leong T, Smithers BM, Michael M, Gebski V, Boussioutas A, Miller D, et al. TOPGEAR: a randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG). BMC Cancer 2015;15:532. https://doi.org/10.1186/s12885-015-1529-x
  9. Slagter AE, Jansen EP, van Laarhoven HW, van Sandick JW, van Grieken NC, Sikorska K, et al. CRITICS-II: a multicentre randomised phase II trial of neo-adjuvant chemotherapy followed by surgery versus neo-adjuvant chemotherapy and subsequent chemoradiotherapy followed by surgery versus neo-adjuvant chemoradiotherapy followed by surgery in resectable gastric cancer. BMC Cancer 2018;18:877. https://doi.org/10.1186/s12885-018-4770-2
  10. Amin MB, Edge SB, Greene FL. AJCC Cancer Staging Manual. 8th ed. New York (NY): Springer; 2017.
  11. Ikoma N, Blum M, Estrella JS, Das P, Hofstetter WL, Fournier KF, et al. Evaluation of the American Joint Committee on Cancer 8th edition staging system for gastric cancer patients after preoperative therapy. Gastric Cancer 2018;21:74-83. https://doi.org/10.1007/s10120-017-0743-4
  12. Lowy AM, Mansfield PF, Leach SD, Pazdur R, Dumas P, Ajani JA. Response to neoadjuvant chemotherapy best predicts survival after curative resection of gastric cancer. Ann Surg 1999;229:303-308. https://doi.org/10.1097/00000658-199903000-00001
  13. Ajani JA, Winter K, Okawara GS, Donohue JH, Pisters PW, Crane CH, et al. Phase II trial of preoperative chemoradiation in patients with localized gastric adenocarcinoma (RTOG 9904): quality of combined modality therapy and pathologic response. J Clin Oncol 2006;24:3953-3958. https://doi.org/10.1200/JCO.2006.06.4840
  14. Yoshikawa T, Tanabe K, Nishikawa K, Ito Y, Matsui T, Kimura Y, et al. Induction of a pathological complete response by four courses of neoadjuvant chemotherapy for gastric cancer: early results of the randomized phase II COMPASS trial. Ann Surg Oncol 2014;21:213-219. https://doi.org/10.1245/s10434-013-3055-x
  15. Badgwell B, Blum M, Estrella J, Chiang YJ, Das P, Matamoros A, et al. Predictors of survival in patients with resectable gastric cancer treated with preoperative chemoradiation therapy and gastrectomy. J Am Coll Surg 2015;221:83-90. https://doi.org/10.1016/j.jamcollsurg.2015.04.004
  16. Ikoma N, Das P, Hofstetter W, Ajani JA, Estrella JS, Chen HC, et al. Preoperative chemoradiation therapy induces primary-tumor complete response more frequently than chemotherapy alone in gastric cancer: analyses of the National Cancer Database 2006-2014 using propensity score matching. Gastric Cancer 2018;21:1004-1013. https://doi.org/10.1007/s10120-018-0832-z
  17. Becker K, Langer R, Reim D, Novotny A, Meyer zum Buschenfelde C, Engel J, et al. Significance of histopathological tumor regression after neoadjuvant chemotherapy in gastric adenocarcinomas: a summary of 480 cases. Ann Surg 2011;253:934-939. https://doi.org/10.1097/SLA.0b013e318216f449
  18. Stark AP, Ikoma N, Chiang YJ, Estrella JS, Das P, Minsky BD, et al. Characteristics and survival of gastric cancer patients with pathologic complete response to preoperative therapy. Ann Surg Oncol 2019;26:3602-3610. https://doi.org/10.1245/s10434-019-07638-8
  19. Ikoma N, Hofstetter WL, Estrella JS, Das P, Minsky BD, Fournier KF, et al. The ypT category does not impact overall survival in node negative gastric cancer. J Surg Oncol 2018;117:1721-1728. https://doi.org/10.1002/jso.25081
  20. Ikoma N, Estrella JS, Hofstetter W, Das P, Minsky BD, Ajani JA, et al. Nodal downstaging in gastric cancer patients: promising survival if ypN0 is achieved. Ann Surg Oncol 2018;25:2012-2017. https://doi.org/10.1245/s10434-018-6471-0
  21. American College of Surgeons. National Cancer Database [Internet]. Chicago (IL): American College of Surgeons; c2020 [cited 2020 May 6]. Available from: https://www.facs.org/quality-programs/cancer/ncdb.
  22. Austin PC. Some methods of propensity-score matching had superior performance to others: results of an empirical investigation and Monte Carlo simulations. Biom J 2009;51:171-184. https://doi.org/10.1002/bimj.200810488
  23. Zanoni A, Verlato G, Giacopuzzi S, Motton M, Casella F, Weindelmayer J, et al. ypN0: Does it matter how you get there? Nodal downstaging in esophageal cancer. Ann Surg Oncol 2016;23:998-1004. https://doi.org/10.1245/s10434-016-5440-8
  24. Blackham AU, Yue B, Almhanna K, Saeed N, Fontaine JP, Hoffe S, et al. The prognostic value of residual nodal disease following neoadjuvant chemoradiation for esophageal cancer in patients with complete primary tumor response. J Surg Oncol 2015;112:597-602. https://doi.org/10.1002/jso.24050
  25. Portuondo JI, Massarweh NN, Zhang Q, Chai CY, Tran Cao HS. Nodal downstaging as a treatment goal for node-positive pancreatic cancer. Surgery 2019;165:1144-1150. https://doi.org/10.1016/j.surg.2018.12.009
  26. Al-Batran SE, Hofheinz RD, Pauligk C, Kopp HG, Haag GM, Luley KB, et al. Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trial. Lancet Oncol 2016;17:1697-1708. https://doi.org/10.1016/S1470-2045(16)30531-9
  27. Al-Batran SE, Homann N, Pauligk C, Goetze TO, Meiler J, Kasper S, et al. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trial. Lancet 2019;393:1948-1957. https://doi.org/10.1016/S0140-6736(18)32557-1
  28. Kim S, Paget-Bailly S, Messager M, Nguyen T, Mathieu P, Lamfichekh N, et al. Perioperative docetaxel, cisplatin, and 5-fluorouracil compared to standard chemotherapy for resectable gastroesophageal adenocarcinoma. Eur J Surg Oncol 2017;43:218-225. https://doi.org/10.1016/j.ejso.2016.06.395
  29. Watson S, de la Fouchardiere C, Kim S, Cohen R, Bachet JB, Tournigand C, et al. Oxaliplatin, 5-fluorouracil and nab-paclitaxel as perioperative regimen in patients with resectable gastric adenocarcinoma: a GERCOR phase II study (FOXAGAST). Eur J Cancer 2019;107:46-52. https://doi.org/10.1016/j.ejca.2018.11.006
  30. Ajani JA, Mansfield PF, Crane CH, Wu TT, Lunagomez S, Lynch PM, et al. Paclitaxel-based chemoradiotherapy in localized gastric carcinoma: degree of pathologic response and not clinical parameters dictated patient outcome. J Clin Oncol 2005;23:1237-1244. https://doi.org/10.1200/JCO.2005.01.305
  31. Ajani JA, Mansfield PF, Janjan N, Morris J, Pisters PW, Lynch PM, et al. Multi-institutional trial of preoperative chemoradiotherapy in patients with potentially resectable gastric carcinoma. J Clin Oncol 2004;22:2774-2780. https://doi.org/10.1200/JCO.2004.01.015
  32. Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol 2009;27:851-856. https://doi.org/10.1200/JCO.2008.17.0506
  33. Xiang M, Chang DT, Heestand GM, Pollom EL. Survival after neoadjuvant approaches to gastroesophageal junction cancer. Gastric Cancer 2020;23:175-183. https://doi.org/10.1007/s10120-019-00980-6
  34. Lane WO, Nussbaum DP, Sun Z, Blazer DG. Preoperative radiation therapy in the surgical management of gastric and junctional adenocarcinoma: should lymph node retrieval guidelines be altered? J Surg Oncol 2018;117:1708-1715. https://doi.org/10.1002/jso.25068
  35. Karimi P, Islami F, Anandasabapathy S, Freedman ND, Kamangar F. Gastric cancer: descriptive epidemiology, risk factors, screening, and prevention. Cancer Epidemiol Biomarkers Prev 2014;23:700-713. https://doi.org/10.1158/1055-9965.EPI-13-1057
  36. Kwee RM, Kwee TC. Imaging in assessing lymph node status in gastric cancer. Gastric Cancer 2009;12:6-22. https://doi.org/10.1007/s10120-008-0492-5
  37. Shapiro J, Biermann K, van Klaveren D, Offerhaus GJ, Ten Kate FJ, Meijer SL, et al. Prognostic value of pretreatment pathological tumor extent in patients treated with neoadjuvant chemoradiotherapy plus surgery for esophageal or junctional cancer. Ann Surg 2017;265:356-362. https://doi.org/10.1097/SLA.0000000000001630

피인용 문헌

  1. Duration of Perioperative Chemotherapy in Locally Advanced Gastric Cancer: A “Less Is More” Question When ypN0 Is Achieved vol.11, 2021, https://doi.org/10.3389/fonc.2021.775166
  2. Lymph Node Involvement in Advanced Gastric Cancer in the Era of Multimodal Treatment-Oncological and Surgical Perspective vol.13, pp.10, 2020, https://doi.org/10.3390/cancers13102509
  3. Validating a nodal regression system for gastric cancer: An ancillary cohort study of the GASTRODOC trial vol.94, 2020, https://doi.org/10.1016/j.ijsu.2021.106112